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Abstract
BACKGROUND: Bioavailability and bioequivalence studies required by regulations to ensure therapeutic 
equivalence between a pharmaceutically equivalent test product and a reference product.
AIM: This study aimed to evaluate the bioavailability performance between the optimum formula of OROS dispersible 
tablet-metoclopramide dosage forms (FCL-6) and the Primperan® as the reference product.
METHODS: The FCL-6 formula was design by simplex lattice design model with a three components mixture of 
excipients: Solid tapai extract, corn starch, and Avicel. The optimum formula of OROS dispersible tablet (ODT)-
metoclopramide consists of solid tapai extract (27.038 mg), corn starch (27.407 mg), and Avicel (53.555 mg), 
metoclopramide hydrochloric acid (HCl) (10.00 mg), LH-11 (22.50 mg), aspartame (5.00 mg), talcum BP (3.00 mg), 
and Mg stearate (1.50 mg). The in vivo test was done by cross-over design method using six rabbits. The level 
of metoclopramide concentration from in vivo test was measured by high-performance liquid chromatography 
instrument.
RESULTS: The study revealed that the tmax, Cmax, and area under curve (AUC) of ODT-metoclopramide FCL-6 were 
60 min, 1.95 ± 0.13 µg/mL, and 1118.20 ± 150 µg/mL. min consecutively. The Cmax and the concentration of the drug 
absorbed in the blood (AUC) of ODT-metoclopramide were larger than Primperan® tablets. Statistical data of the 
optimized ODT-metoclopramide compared with Primperan® showed that the Cmax and AUC significance values were 
<0.05 (p < 0.05). 
CONCLUSION: The optimized formula of ODT-metoclopramide revealed a better characteristic of Cmax and AUC 
concentration compared with Primperan®. The optimized ODT-metoclopramide with tapai extract was found to be 
promising to improved bioavailability of metoclopramide.
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Introduction
OROS dispersible tablets (ODTs) are a solid 
dosage form containing active ingredients of drugs and 
destroyed quickly within a few seconds when placed 
on the surface of the tongue [1], [2], [3]. ODTs have 
several advantages such as disintegrate rapidly on the 
tongue, usually only takes a few seconds without the 
need for water to swallow, providing rapid early onset 
of action, and significantly increase the bioavailability 
of the conventional dosage form [4], [5], [6]. The drug 
administration problem occurred by the geriatric or 
pediatrics in consume the solid dosage form/tablets 
could be resolve by ODT preparation [7], [8].
Metoclopramide administered to the patients 
who have travel sickness and may have no water 
supply at the time to take the medicine and it was 
chosen as a model drug in this study. The ODT-
metoclopramide formulas were design by simplex 
lattice design model with a three components mixture 
of excipients (solid tapai extract, corn starch, and 
Avicel). The optimum formula of ODT-metoclopramide 
(FCL-6) consists of solid tapai extract (27.038 mg), 
corn starch (27.407 mg), and Avicel (53.555 mg), 
metoclopramide HCl (10.00 mg), LH-11 (22.50 mg), 
aspartame (5.00 mg), talcum BP (3.00 mg), and Mg 
stearate (1.50 mg) [9].
Bioavailability and bioequivalence studies 
required by regulations to ensure therapeutic 
equivalence between a pharmaceutically equivalent 
test product and a reference product. Several in vivo 
and in vitro methods used to measure product quality. 
Bioequivalence documentation was also needed to 
establish links between early and late clinical trial 
formulations, formulations used in clinical trials and 
stability studies, clinical trial formulations and to be 
marketed drug products, and other comparisons, as 
appropriate. In each comparison, the new formulation or 
new method of manufactured shall be the test product 
and the prior formulation (or respective method of 
manufacture) shall be the reference product [10], [11]. 
This study aims to study the bioavailability performance 
between the optimum formula of ODT-metoclopramide 
dosage forms (FCL-6) and the Primperan® as the 
reference product.
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Materials and Methods
Materials that used in this study were 
metoclopramide (PT. First Medifarma), acetic acid 
(glacial), acetonitrile, methanol, aqua pro-injection, 
metoclopramide HCl BP (PT. Kairos Tritunggal), 
trichloroacetic acid (TCA) 20%, and heparin. High-
performance liquid chromatography (HPLC) (Agilent 
1120 Compact LC), Colom ODS C-18, solvent container 
(Oberol), vial (Agilent), animal box, vacuum pump 
(Gast DO), sonicator (Branson), paper membrane 
filter cellulose nitrate 0.45 µm (Whatman), paper 
membrane filter nylon 0.45 µm (Whatman), PTFE 
02 µm (Whatman), Primperan® (PT. SOHO), Avicel PH 
102, Solid tapai extract, Corn starch, LH-11, and Mg 
stearate were used.
The in vivo test was done by cross-over 
design method [12] using six rabbits. The rabbits 
used in this study were male, aged 6 months old and 
weighed 1.5–2.0 kg. The rabbits were acclimatized for 
2 weeks to adapt with the environment. Administration 
of metoclopramide in rabbit by this method is shown 
in Table 1. The conventional Primperan® tablets were 
used as a positive control in evaluating the FCL-6 
bioavailability performance.
The rabbit fasted for approximately 12 h and 
administered with the optimized ODT-metoclopramide 
(FCL-6) and Primperan® on an oral basis which is 
shown in Table 1. The rabbit’s blood was taken through 
a marginal vein at certain intervals of time: 10, 20, 30, 
45, 60, 90, 120, 180, 300, and 420 min using a 1.0 mL 
syringe. The needle was rinsed first with heparin. The 
rabbit blood then inserted into the centrifuge tube that 
has two drops of heparin. Then, 1.0 mL of TCA 20% 
was added to the tube and homogenized by vortex 
instrument. The tube centrifuged at 3000 rpm for 10 min 
then the supernatant filtered using a 0.2 µm PTFE filter 
membrane and measured using a HPLC instrument by 
injecting 10 µL of supernatant.
Bioavailability test of metoclopramide in plasma 
of rabbit blood was measured by next procedure: The 
rabbits were given the oral medications in accordance 
with the bioequivalence test design that is shown in 
Table 2. At intervals, 10, 20, 30, 45, 90, 120, 180, 300, 
and 420 min, the rabbits blood were taken with the help 
of a 1.0 mL syringe that has been rinsed with heparin, 
transferred to a centrifuge tube containing two drops 
of heparin and added TCA 20% 1 mL, centrifuged at 
3000 rpm for 10 min then take the supernatant. The 
supernatant filtered with PTFE 0.2 µm filter membrane 
then determined the concentration of metoclopramide 
using HPLC instrument. Data analysis has been 
carried out using Microsoft Excel to calculate the value 
of tmax, Cmax, and area under curve (AUC). The AUC 
concentration was determined by trapezoidal formula. 
The statistical comparison of Cmax and AUC values 
between the two formulas was analyzed using the 
independent sample t-test method.
Results
The study result revealed an average 
maximum peak time (tmax) was 60 min. This means 
that the maximum concentration was reached at 
minute 60. The relationship between plasma drug 
concentration (C) and cumulative percentage of time-
off drugs (t) of optimized ODT-metoclopramide (FCL-6) 
and Primperan® revealed in Figure 1.
Figure 1: The relationship of mean drug concentrations versus times 
in rabbits plasma
Based on the data in Figure 1, it can be 
determined tmax, Cmax, and AUC. The results revealed 
in Table 2. It showed that the maximum concentration 
(Cmax Cmax) of FCL-6 (1.94456 ± 0.1340 µg/mL) was 
larger than Primperan tablets (1.61240 ± 0.1843 µg/mL). 
This means that FCL-6 was absorbed faster than 
Primperan®.
Table 2: The values of tmax, Cmax, and AUC
Formula Means ± SD
tmax (min) Cmax (µg/mL) AUC (µg/mL. min)
FCL-6 60 1.95 ± 0.1340 1118.20 ± 149.99
Primperan® 60 1.61 ± 0.1843 759.26 ± 108.46
AUC: Area under curve.
The AUC calculated by the trapezoidal 
formula (against the amount of the drug absorbed in 
the blood). AUC of FCL-6 (1118.20 ± 149.99 µg/mL 
min) was larger compared with Primperan® tablets 
(854.45 ± 251.7 µg/mL min). This is because STP has 
a highly soluble nature in water and Avicel and CS 
have disintegrating agent properties so that FCL-6 was 
more rapidly dissolved and absorbed. As the result, the 
amount of the drug absorbed in the blood (AUC) was 
larger than Primperan® tablets [13].
The bioequivalence data between optimized 
ODT-metoclopramide and Primperan® revealed in 
Table 3.
Table 1: Administration of FCL-6 and Primperan® in rabbits
Treatment I Treatment II
Rabbit Drug Rabbit Drug
1 A Rest for 1 week 1 B
2 A 2 B
3 A 3 B
4 B 4 A
5 B 5 A
6 B 6 A
A = FCL-6, B = Tablet Primperan®10 mg.
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Table 3 shows that the Relative Bio-Availability 
(RBA) was larger than 1.25 and larger than 0.8, tmax and 
Cmax were in range. Based on these results, the two 
preparations were claimed to be not bioequivalence. 
This condition was occur because the optimized ODT-
metoclopramide contains water-soluble STP, Avicel and 
CS have disintegrator properties so that this optimized 
ODT-metoclopramide dissolves and absorbed faster 
than Primperan® tablets. As the result, the Cmax and the 
concentration of the drug absorbed in the blood (AUC) 
of ODT-metoclopramide (FCL-6) were larger than 
Primperan® tablets.
Table 3: Optimized ODT-metoclopramide and Primperan® 
bioequivalence data
Parameters Comparing value A/B Range parameters
AUC 1.47 0.8 <AUC (A/B)< 1.25
tmax 1 0.8 < tmax (A/B)< 1.25
Cmax 1.21 0.8 < Cmax (A/B) < 1.25
A= FCL-6, B= Primperan®. AUC: Area under curve, ODT: OROS dispersible tablet
Results of the FCL-6 and Primperan® 
parameters of bioavailability statistically analysis are 
shown in Table 4.
Table 4: Result of statistical data analysis of the FCL-6 and 
Primperan® test
Treatments No. of treatment Means±SD p
Cmax FCL-6 6 1.94456 ± 0.1340 0.005
Cmax Primperan 1.61240 ± 0.1843
AUC FCL-6 6 1118.20 ± 149.99 0.001
AUC Primperan 854.45 ± 251.7
AUC: Area under curve
Statistical data of the optimized and Primperan ® 
ODT-metoclopramide testing with t-test in Table 4 showed 
that the Cmax and AUC significance values were <0.05 
(p < 0.05) and this means that at a 95% confidence level, 
there was a significant difference between Cmax and AUC 
value of the two drugs compared.
Discussion
The study was determined pharmacokinetic 
parameters of the optimized ODT-metoclopramide 
formula, FCL-6, from the observed plasma concentration 
time profiles. The marketed preparation through oral 
administration, Primperan®, was selected for reference 
product since these preparations are already clinically 
proven. From bioavailability studies, it can be concluded 
that FCL-6 was capable to deliver the drug in systemic 
circulation since the RBA by ODT formulation with tapai 
extract was found to be 147%. The comparison of Cmax 
and AUC value also showed the significantly differences 
between FCL-6 and Primperan® where FCL-6 showed 
the superiority to Primperan®. These facts are in similar 
with the findings revealed by Shyamala and Narmada [4], 
Pawar and Junagade [5], and Shah and Mehta [6] that 
ODT formulation was capable to significantly increase 
the bioavailability of the conventional dosage form.
The AUC value of FCL-6 (1118.20 ± 
149.99 µg/mL. min) showed the higher value 
when compared with the AUC value (2716±4.62 
ng.h/mL) from Galgatte and Chaudhari [14] that study 
the bioavailability of mucoadhesive thermo reversible 
in situ gel-metoclopramide that administered nasally 
to New Zealand rabbits. Meanwhile, another study by 
Ward et al. [15] stated that the intranasal route did not 
allow rapid absorption of the metoclopramide and was 
not associated with greater bioavailability than the oral 
route. Therefore, the order of bioavailability is i.v. > ODT 
> nasal [14], [15], [16].
The RBA study also referred as a pilot 
pharmacokinetics study was used by the drug 
development sponsor to assess potential in vivo 
performance differences between dosage forms. The 
data obtained from the RBA study allow the sponsor 
to move forward in clinical development with a new 
dosage form [17], [18], [19], [20]. The RBA of FCL-6 
(147%) also showed the higher value compare with 
the RBA value of metoclopramide nasal spray dosage 
form (62.3%) that mentioned by Li et al. study [21]. 
It revealed that the optimized ODT-metoclopramide 
with tapai extract (FCL-6) has the ability to increased 
bioavailability of metoclopramide.
Conclusion
It can be concluded that the optimized 
formula of ODT-metoclopramide (FCL-6) has a better 
characteristic of Cmax and AUC concentration compared 
with Primperan®. The optimized ODT-metoclopramide 
with tapai extract dosage forms (FCL-6) was found to be 
promising to improved bioavailability of metoclopramide.
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